Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Jun. 30, 2026	Consolidated Financial Statements for Years ended March 31, 2026 and 2025	Finances
Jun. 25, 2026	Matters Concerning Controlling Shareholders, Etc.	Corporate
Jun. 19, 2026	Wegovy Subcutaneous Injection, Co-Promoted with Novo Nordisk Pharma, Approved in Japan for Metabolic Dysfunction-Associated Steatohepatitis (MASH)	Products
Jun. 16, 2026	Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia（PDF/130KB）	R&D
Jun. 10, 2026	Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia	R&D
Jun. 02, 2026	Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026（PDF/473KB）	R&D

Jul. 31, 2026	1st Quarter of FY2026 financial results announcement (scheduled to be disclosed at 3:30 p.m.)
Jun. 25, 2026	206th Annual Shareholders’ Meeting